The device, called Tap, collects capillary blood for hemoglobin A1c testing, which is commonly used to monitor blood sugar levels in diabetic or pre-diabetic patients, according to a news release.
To draw blood, clinicians position the device on a patient’s upper arm and “with just a ‘tap’, blood is collected,” according to the company’s website.
Seventh Sense Biosystems’ said it’s working with the FDA to offer additional blood testing options, along with an “at home” collection of products.
The Medford, Mass.-based company will launch Tap in the next few months.
More articles on supply chain:
6 must-reads for supply chain leaders this week
UPS to offer Saturday ground delivery services
FDA approves new liquid drug for hypothyroidism
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
